Literature DB >> 24019032

Dyslipidaemia: PCSK9 antibodies: a dividend of the genomics revolution.

Michael H Davidson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24019032     DOI： 10.1038/nrcardio.2013.139

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  11 in total

1.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

Authors:  Jonathan C Cohen; Eric Boerwinkle; Thomas H Mosley; Helen H Hobbs
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

2.  Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels.

Authors:  Daniel Steinberg; Joseph L Witztum
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-08       Impact factor: 11.205

Review 3.  The PCSK9 decade.

Authors:  Gilles Lambert; Barbara Sjouke; Benjamin Choque; John J P Kastelein; G Kees Hovingh
Journal:  J Lipid Res       Date:  2012-07-17       Impact factor: 5.922

4.  Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

Authors:  Jonathan Cohen; Alexander Pertsemlidis; Ingrid K Kotowski; Randall Graham; Christine Kim Garcia; Helen H Hobbs
Journal:  Nat Genet       Date:  2005-01-16       Impact factor: 38.330

5.  Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.

Authors:  Robert P Giugliano; Nihar R Desai; Payal Kohli; William J Rogers; Ransi Somaratne; Fannie Huang; Thomas Liu; Satishkumar Mohanavelu; Elaine B Hoffman; Shannon T McDonald; Timothy E Abrahamsen; Scott M Wasserman; Robert Scott; Marc S Sabatine
Journal:  Lancet       Date:  2012-11-06       Impact factor: 79.321

6.  AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.

Authors:  Nihar R Desai; Payal Kohli; Robert P Giugliano; Michelle L O'Donoghue; Ransi Somaratne; Jing Zhou; Elaine B Hoffman; Fannie Huang; William J Rogers; Scott M Wasserman; Robert Scott; Marc S Sabatine
Journal:  Circulation       Date:  2013-07-24       Impact factor: 29.690

Review 7.  Pharmacological strategies for lowering LDL cholesterol: statins and beyond.

Authors:  Ariel Brautbar; Christie M Ballantyne
Journal:  Nat Rev Cardiol       Date:  2011-02-15       Impact factor: 32.419

8.  Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells.

Authors:  Tommaso Fasano; Xi-Ming Sun; Dilipkumar D Patel; Anne K Soutar
Journal:  Atherosclerosis       Date:  2008-11-06       Impact factor: 5.162

9.  Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis.

Authors:  Yue-Wei Qian; Robert J Schmidt; Youyan Zhang; Shaoyou Chu; Aimin Lin; He Wang; Xiliang Wang; Thomas P Beyer; William R Bensch; Weiming Li; Mariam E Ehsani; Deshun Lu; Robert J Konrad; Patrick I Eacho; David E Moller; Sotirios K Karathanasis; Guoqing Cao
Journal:  J Lipid Res       Date:  2007-04-20       Impact factor: 5.922

10.  Lipoprotein(a) as a cardiovascular risk factor: current status.

Authors:  Børge G Nordestgaard; M John Chapman; Kausik Ray; Jan Borén; Felicita Andreotti; Gerald F Watts; Henry Ginsberg; Pierre Amarenco; Alberico Catapano; Olivier S Descamps; Edward Fisher; Petri T Kovanen; Jan Albert Kuivenhoven; Philippe Lesnik; Luis Masana; Zeljko Reiner; Marja-Riitta Taskinen; Lale Tokgözoglu; Anne Tybjærg-Hansen
Journal:  Eur Heart J       Date:  2010-10-21       Impact factor: 29.983
View more
  3 in total

1.  Beyond anti-PCSK9 therapies: the potential role of resistin inhibitors.

Authors:  Amirhossein Sahebkar
Journal:  Nat Rev Cardiol       Date:  2013-11-12       Impact factor: 32.419

2.  PCSK6-mediated corin activation is essential for normal blood pressure.

Authors:  Shenghan Chen; Pengxiu Cao; Ningzheng Dong; Jianhao Peng; Chunyi Zhang; Hao Wang; Tiantian Zhou; Junhua Yang; Yue Zhang; Elizabeth E Martelli; Sathyamangla V Naga Prasad; Rachel E Miller; Anne-Marie Malfait; Yiqing Zhou; Qingyu Wu
Journal:  Nat Med       Date:  2015-08-10       Impact factor: 53.440

Review 3.  The genetics and screening of familial hypercholesterolaemia.

Authors:  Raymond Henderson; Maurice O'Kane; Victoria McGilligan; Steven Watterson
Journal:  J Biomed Sci       Date:  2016-04-16       Impact factor: 8.410
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.